P2.01-29 The Correlation Between K-Ras Mutant Subsets with TP53 Mutation and PD-L1 in Non-Small Cell Lung Cancer (NSCLC)
Nagla Abdel Karim(Virginia Cancer Institute), Abdul Rafeh Naqash(Oklahoma City University), Alexander I. Spira(Virginia Cancer Specialists), Hirva Mamdani(Wayne State University), Chisom Onuoha(Augusta University), I. Eldesouki(Augusta University Health), Istaq Ahmad(Augusta University Health)
Cited by 0
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Immunotherapy in Lung Cancer: Current Landscape and Future Directions
|Frontiers in Immunology|2022|373
Amivantamab plus Lazertinib in Previously Untreated <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2024|369